Merck Nears 6 Billion Dollar Deal for Terns Pharma
Merck is in advanced talks to acquire biotech firm Terns Pharma for roughly 6 billion dollars in cash. An agreement could be finalized in the coming days.
The pharmaceutical giant Merck & Co., Inc. is reportedly in advanced negotiations to acquire Terns Pharmaceuticals, Inc. in a deal valued at approximately $6 billion. According to a report from the Financial Times on Tuesday, the proposed transaction is expected to be an all-cash agreement, marking a significant strategic move for the New Jersey-based drugmaker. Sources familiar with the matter indicated that the discussions have reached a mature stage and a formal announcement could be made within the next few days. While the acquisition appears to be moving forward, neither company has provided an official response to inquiries regarding the status of the talks. The development, reported from Mexico, comes as Merck continues to seek external innovation to strengthen its pipeline. Terns Pharmaceuticals specializes in developing small-molecule medicines for oncology and metabolic diseases, areas that align with Merck's broader growth objectives.
